Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2017 Oct 24;18(1):180.
doi: 10.1186/s12931-017-0662-2.

The value of blood cytokines and chemokines in assessing COPD

Affiliations
Clinical Trial

The value of blood cytokines and chemokines in assessing COPD

Eric Bradford et al. Respir Res. .

Abstract

Background: Blood biomarkers are increasingly used to stratify high risk chronic obstructive pulmonary disease (COPD) patients; however, there are fewer studies that have investigated multiple biomarkers and replicated in multiple large well-characterized cohorts of susceptible current and former smokers.

Methods: We used two MSD multiplex panels to measure 9 cytokines and chemokines in 2123 subjects from COPDGene and 1117 subjects from SPIROMICS. These biomarkers included: interleukin (IL)-2, IL-6, IL-8, IL-10, tumor necrosis factor (TNF)-α, interferon (IFN)-γ, eotaxin/CCL-11, eotaxin-3/CCL-26, and thymus and activation-regulated chemokine (TARC)/CCL-17. Regression models adjusted for clinical covariates were used to determine which biomarkers were associated with the following COPD phenotypes: airflow obstruction (forced expiratory flow at 1 s (FEV1%) and FEV1/forced vital capacity (FEV1/FVC), chronic bronchitis, COPD exacerbations, and emphysema. Biomarker-genotype associations were assessed by genome-wide association of single nucleotide polymorphisms (SNPs).

Results: Eotaxin and IL-6 were strongly associated with airflow obstruction and accounted for 3-5% of the measurement variance on top of clinical variables. IL-6 was associated with progressive airflow obstruction over 5 years and both IL-6 and IL-8 were associated with progressive emphysema over 5 years. None of the biomarkers were consistently associated with chronic bronchitis or COPD exacerbations. We identified one novel SNP (rs9302690 SNP) that was associated with CCL17 plasma measurements.

Conclusion: When assessing smoking related pulmonary disease, biomarkers of inflammation such as IL-2, IL-6, IL-8, and eotaxin may add additional modest predictive value on top of clinical variables alone.

Trial registration: COPDGene (ClinicalTrials.gov Identifier: NCT02445183 ). Subpopulations and Intermediate Outcomes Measures in COPD Study (SPIROMICS) ( ClinicalTrials.gov Identifier: NCT 01969344 ).

Trial registration: ClinicalTrials.gov NCT02445183 NCT01969344.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

The study protocols were approved by the local ethics committees listed below. Informed written consent was obtained from all participants.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Plasma eotaxin and IL-6 are higher in subjects with COPD. Never smokers (never) and current and former smokers with no COPD (control), mild/moderate COPD (Mild/Moderate), or severe or very severe COPD (Severe)
Fig. 2
Fig. 2
Heat map showing associations between cytokines and chemokines and COPD clinical phenotypes in the COPDGene and SPIROMICS cohorts. The intensity of the color represents the log of the P-value with red indicating positive associations and blue indicating negative associations

Similar articles

Cited by

References

    1. United States. Public Health Service. Office Of The Surgeon General . The health consequences of smoking--50 years of progress : a report of the surgeon general. Rockville: U.S. Department Of Health And Human Services, Public Health Service, Office Of The Surgeon General; 2014.
    1. Vestbo J, Agusti A, Wouters E, et al. Should we view chronic obstructive pulmonary disease differently after Eclipse? A clinical perspective from the study team. Am J Respir Crit Care Med. 2014;189(9):1022–1030. doi: 10.1164/rccm.201311-2006PP. - DOI - PubMed
    1. Agusti A, Sin DD. Biomarkers in COPD. Clin Chest Med. 2014;35(1):131–141. doi: 10.1016/j.ccm.2013.09.006. - DOI - PubMed
    1. Faner R, Tal-Singer R, Riley JH, et al. Lessons from Eclipse: a review of COPD biomarkers. Thorax. 2014;69(7):666–672. doi: 10.1136/thoraxjnl-2013-204778. - DOI - PubMed
    1. Agusti A, Gea J, Faner R. Biomarkers, the control panel and personalized COPD medicine. Respirology. 2016;21(1):24–33. doi: 10.1111/resp.12585. - DOI - PubMed

Associated data